Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
8.02
-0.14 (-1.67%)
Jun 5, 2025, 4:00 PM - Market closed
Addex Therapeutics Revenue
In the year 2024, Addex Therapeutics had annual revenue of 410.04K CHF, down -74.64%. Addex Therapeutics had revenue of 1.51K in the quarter ending December 31, 2024, a decrease of -99.02%.
Revenue (ttm)
410.04K CHF
Revenue Growth
-74.64%
P/S Ratio
15.11
Revenue / Employee
205,021 CHF
Employees
2
Market Cap
6.84M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ADXN News
- 2 days ago - Addex Convenes Annual General Meeting 2025 - GlobeNewsWire
- 24 days ago - Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - GlobeNewsWire
- 5 weeks ago - Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery - GlobeNewsWire
- 5 weeks ago - Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Addex Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 - GlobeNewsWire
- 5 months ago - Addex to Present at the 2025 Swiss Equities Baader Conference - GlobeNewsWire
- 6 months ago - Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript - Seeking Alpha